Results of SGK1 Inhibition in Patient- and Genotype Specific Re-Engineered Heart Cells with Congenital Long QT Syndrome and a model of Drug-Induced QT Prolongation to be presented at the AHA Scientific Sessions 2022 taking place November 5-7, 2022, in Chicago

We are pleased to appoint Dr. Debra Odink to President & CDO, and Dr. Shi Yin Foo to our Board. Both individuals bring impressive depth of development and company building expertise, which will be crucial as Thryv moves into clinical trials later this month.

We are excited to announce the evolution of our portfolio to include treatments for resistant and rare cancers. The new name, Thryv Therapeutics, embodies our commitment to relentlessly pursue therapies which provide lifelong benefits to patients, families, doctors, nurses and stakeholders.

Dr. Campeau will collaborate with Dr. McDonnell and his research team at Duke University to evaluate SGK1 inhibitors as potential treatments for people with breast and prostate cancer.

A major objective after our Series A financing, has been to enrich our Board with experienced, respected and highly accomplished drug development executives as we advance our clinical programs.

LQTT has completed US$19 million Series A financing led by Amplitude Ventures and included new investments from existing investors. We’re advancing a series of in-licensed compounds discovered and developed by Sanofi S.A. that inhibit SGK1.

In July 2021, a team of former Indiana University Swim Team are competing in the Trans Tahoe Relay race to raise awareness of Long QT Syndrome and the need for advanced treatments, while raising funds for 4-yr old Isla who has LQT3.

Amplitude Ventures exceeded their CAD$200M raise target and attracted investment from across the country and internationally. Amplitude is an early seed investor of LQTT.

Dr. Saumya Das, PhD MD, answers some tough questions about his research and the difficulties of treating individuals with a chronic syndrome.

Marc-Olivier Sirard, CPA, senior investment advisor at Fonds de solidarité FTQ, and Dr. Saumya Das, PhD, MD, Director of the Resynchronization and Advanced Cardiac Therapeutics Program at Massachusetts General Hospital, join our board of directors.

Dave Hutton is a school teacher by profession, and a Long QT Syndrome caregiver by devotion. Upon his daughter Isla’s diagnosis with Long QT Syndrome Type 3 in 2016, Dave left teaching to be the full-time caregiver to his little girl.

Alexander Thomas is a 17 year-old dance prodigy born in South Florida. Alexander also has Long QT Syndrome, a condition shared by his mother, Palmire, and his brother, Adrien. This is their journey, shared with the LQTS community.

Research collaboration with the Mayo Clinic in Rochester, Minnesota to evaluate novel pharmacologic treatments for LQTS, an arrhythmia associated with a prolonged QT interval that can cause sudden death.

Long QT Syndrome is a rare disorder that is often undiagnosed. LQTS causes an elongation between the Q and T waves during a heart beat. The lengthening of these waves can cause unexpected and life-threatening arrhythmias.

LQT Therapeutics raised up to C$1.8M seed funding led by Fonds de solidarité FTQ and other founding investors. Our aim is to develop a series of preclinical compounds as new treatment options for Long QT Syndrome and other arrhythmias.